Shelley B. Thunen Sells 31,772 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXSTGet Free Report) CFO Shelley B. Thunen sold 31,772 shares of the stock in a transaction on Friday, January 26th. The stock was sold at an average price of $47.11, for a total transaction of $1,496,778.92. Following the completion of the sale, the chief financial officer now owns 6,791 shares in the company, valued at approximately $319,924.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

RxSight Price Performance

Shares of RXST opened at $46.46 on Wednesday. RxSight, Inc. has a 1-year low of $12.21 and a 1-year high of $48.77. The stock has a market cap of $1.67 billion, a PE ratio of -26.86 and a beta of 1.19. The firm has a 50-day simple moving average of $39.32 and a two-hundred day simple moving average of $31.88.

RxSight (NASDAQ:RXSTGet Free Report) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.07. The firm had revenue of $22.20 million during the quarter, compared to analysts’ expectations of $20.81 million. RxSight had a negative net margin of 71.87% and a negative return on equity of 39.77%. As a group, sell-side analysts expect that RxSight, Inc. will post -1.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RXST. JPMorgan Chase & Co. grew its holdings in shares of RxSight by 4,739.2% in the first quarter. JPMorgan Chase & Co. now owns 565,506 shares of the company’s stock valued at $9,433,000 after purchasing an additional 553,820 shares in the last quarter. Atika Capital Management LLC acquired a new position in shares of RxSight in the second quarter valued at approximately $14,803,000. BlackRock Inc. grew its holdings in shares of RxSight by 30.6% in the second quarter. BlackRock Inc. now owns 1,629,928 shares of the company’s stock valued at $46,942,000 after purchasing an additional 382,119 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of RxSight by 17.3% in the third quarter. Artisan Partners Limited Partnership now owns 2,437,765 shares of the company’s stock valued at $67,989,000 after purchasing an additional 359,295 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in RxSight by 89.1% in the first quarter. Vanguard Group Inc. now owns 638,813 shares of the company’s stock worth $7,908,000 after acquiring an additional 301,055 shares during the last quarter. Institutional investors and hedge funds own 66.51% of the company’s stock.

Analysts Set New Price Targets

RXST has been the topic of a number of research reports. Stifel Nicolaus initiated coverage on shares of RxSight in a research note on Tuesday, December 12th. They issued a “buy” rating and a $40.00 price objective on the stock. Wells Fargo & Company upgraded shares of RxSight from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $31.00 to $42.00 in a research report on Wednesday, December 13th. Oppenheimer raised their price target on shares of RxSight from $50.00 to $54.00 and gave the company an “outperform” rating in a research report on Monday. Needham & Company LLC raised their price target on shares of RxSight from $35.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, January 8th. Finally, Morgan Stanley started coverage on shares of RxSight in a report on Monday, December 4th. They set an “overweight” rating and a $36.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $37.63.

View Our Latest Stock Report on RXST

About RxSight

(Get Free Report)

RxSight, Inc, an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Further Reading

Insider Buying and Selling by Quarter for RxSight (NASDAQ:RXST)

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.